Trial
NCT00916201
Evaluation Study of New Compounds With Potential Use in Schizophrenia
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Central Institute of Mental Health, Mannheim
Collaborators
Max Planck Institute for Metabolism Research
Condition
Schizophrenia
Intervention
URB597
Why stopped
Lack of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-21